MedTrace Logo

Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)

NCT00839176 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2013-11-19

No results posted yet for this study

Summary

The primary objective of this Phase IIa trial is to determine the effective dose and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression disorder (MDD). The secondary objectives of this trial are to evaluate the safety and quality of life in subjects with MDD receiving RX-10100 treatment.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

RX-10100

Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks

Sponsors & Collaborators

  • Rexahn Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Christine Peterson, PhD · Rexahn Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-09-30
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839176 on ClinicalTrials.gov